Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ganaplacide (KAF156) + lumefantrine solid dispersion for uncomplicated falciparum malaria
2020-003284-25Phase 2
- Sponsor
- Novartis
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ganaplacide and lumefantrine in Malaria (4 arms), sponsored by Novartis. Primary endpoint: PCR-corrected adequate clinical and parasitological response at Day 29.
02
Drugs
ganaplacidelumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on 2020-003284-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003284-25.